knowledge -WSS

knowledge

author：comprehensive 2025-09-29 21:14:39 - browse：29

Photo illustration of Chris Viehbacher -- biotech coverage from STAT — Chris Viehbacher took over as Biogen CEO in November. Suzanne Kreiter/Globe staff; Photo illustration Alex Hogan/STAT

This was supposed to be the new Biogen. When Chris Viehbacher, a respected pharmaceutical executive, took over as CEO in November, Wall Street saw him as a steadying force for the wayward company and a strong personality who would stand up to its quarrelsome board.

Instead, Biogen’s board has saddled Viehbacher with the first crisis of his tenure at the company. Alex Denner, a long-time director, nominated a biotech executive who is also the mother of his child to succeed him on the board, and Biogen chose not to disclose the couple’s relationship to shareholders, an omission that shocked people close to the company and undermined the notion that Biogen was changing for the better.

“It’s just disappointing to see after all the criticism that has been levied at the company over the last few years, there really seems to be no self-awareness going into this recommendation,” said Brian Skorney, a securities analyst at Baird who covers Biogen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： ADA: All diabetes patients should be screened for liver condition

focus

WSS

FDA does about

House looks to weaken Medicare negotiation

Tuskegee Airman Raymond Cassagnol dies at 102

Biden slams SCOTUS affirmative action decision: 'Discrimination still exists in America'

The simple reason for the increase in autism diagnosis

International team creates first chimeric human

focus

knowledge

hotspot

Peter Hotez and the public health issue of online harassment

FogPharma raises $145 million in rare Series E round

How to save PrEP access — and even expand it

An inside look at PIPEs, biotech's buzzy new financing tool

DIEP, the 'gold standard' of breast reconstruction, is under threat

Congress gives doctors Medicare pay bump

Medicare details structure of new drug price negotiation program

ALS groups 'won't be played again' by the FDA, drug sponsors

In Memoriam: Notable people who died in 2023

Covid isolation guidance eased by the CDC

hotspot

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

International team creates first chimeric human

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

Scientists unlock the key to scar

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

focus

focus

Wikipedia

focus